Novo tests new Wegovy pricing as competition intensifies
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Maura Kearns/Axios
Novo Nordisk is testing new Wegovy pricing across telehealth platforms — a sign it's rethinking how to sell its once-dominant weight-loss drugs under pressure from Eli Lilly and digital health upstarts.
Why it matters: The weight-loss drug boom is entering a new phase where access may matter as much as the drugs themselves.
Driving the news: Novo on Tuesday launched a subscription-style pricing model for Wegovy, offering lower monthly costs for patients who commit to three, six or 12 months.
- The program is available through telehealth platforms including Ro, Weight Watchers and LifeMD, with Hims & Hers and others coming soon.
Between the lines: Novo is trying to standardize pricing across telehealth channels while avoiding broader list price cuts.
- The subscription model also helps lock in patients — key in a category where long-term adherence drives results and revenue.
- Weight Watchers says the offering is part of its broader push into integrated GLP-1 care, combining prescriptions with coaching and clinical support.
By the numbers: Wegovy injections cost as low as $249/month with a 12-month subscription, with higher prices for shorter commitments.
- Pill versions follow a similar structure, also dropping to $249/month at longer commitments.
Yes, but: The program mainly targets self-pay patients, while insured patients may pay as little as $25/month through other programs.
- Total costs can still vary depending on the platform and any added clinical or subscription fees.
State of play: Eli Lilly is gaining share with Zepbound and backing it with aggressive marketing.
- Telehealth players like Ro, Hims & Hers and Noom are competing on easier access, bundled care and pricing transparency.
Zoom out: Drugmakers are increasingly relying on telehealth platforms as distribution and engagement layers — blurring the line between pharma and direct-to-consumer care.
The bottom line: Novo isn't just competing on the drug itself — it's competing on price, access and convenience in a rapidly evolving obesity market.
More from Axios:
